Skip to content

Trial · Interventional

TerminatedPhase 2Registry data

A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

NCTNCT00267527 (opens ClinicalTrials.gov in a new tab)Other idGH100-013
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Terminated
Phase
Phase 2
Enrollment
120 participants
Sponsor
ConjuChem · Industry
Design
Randomized · Double masking
Countries
Not stated
Start
Dec 2005
Primary completion
Not stated
Completion
Sept 2006
First posted
21 Dec 2005 (estimated)
Last update posted
16 Oct 2006 (estimated)
Conditions
Obesity · HIV Infections

Timeline

1 trial · 1 stopped early

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200520062007
  1. Ph 2

    A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

    NCT00267527

    Dec 2005 to Sept 2006

    Terminated

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC 1295 or placebo. The objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity.

Interventions

  • CJC 1295Drug

Arms0

The registry lists no arms for this trial.

Primary outcomes0

Outcomes the sponsor listed as primary.

The registry lists no primary outcome.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 65 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Age 18-65 on stable antiviral regimen * Documented HIV infection * HIV associated visceral obesity * Body mass index (BMI) \> 24 and \< 30 kg/m2 Exclusion Criteria: * Diabetes * Use of growth hormone (GH) or other GH secretagogues * Use of systemic glucocorticoids, * Use of megestrol acetate or other appetite stimulants, * Use of general anorexigenic or weight-reducing agents, or * Use of androgens, other than testosterone replacement therapy for male hypogonadism at physiological doses and on a stable regimen for at least 6 months prior to randomization.

PepBank is a research reference. Talk to a doctor before you use any peptide.